Teva Pharmaceutical ( Teva Pharmaceutical )

Teva Pharmaceutical

Teva Pharmaceutical's picture

About Teva Pharmaceutical

The foundation of our success, and at the heart of Teva, is our vision to be the most indispensable medicines company for the world, executing on our obligation to our patients, customers, shareholders and employees.

Established in 1901, today we rank among the 10 top pharmaceutical companies in the world. Headquartered in Israel, Teva is active in 60 countries, with over 46,400 dedicated employees worldwide.

Teva Pharmaceutical press release, blog etc

09/18/2018 - 03:22 Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement
09/13/2018 - 20:15 Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection
09/13/2018 - 19:55 Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults
09/11/2018 - 20:52 Teva to Present at the Morgan Stanley Global Healthcare Conference
09/03/2018 - 23:55 Teva Announces $400 Million Debt Tender Offer
08/16/2018 - 03:55 Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
08/06/2018 - 06:34 Teva Announces Updated Indication and Vial Presentation for GRANIX (tbo-filgrastim) Injection in United States
07/17/2018 - 20:16 Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report
07/09/2018 - 06:41 Teva Announces Launch of a Generic Version of Uceris in the United States
06/28/2018 - 19:16 Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Societys 60th Annual Scientific Meeting
06/15/2018 - 09:49 Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
05/23/2018 - 04:21 Teva Confirms September PDUFA Date for Fremanezumab
05/18/2018 - 14:58 CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
05/15/2018 - 09:43 Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
05/02/2018 - 07:20 Teva to Present AUSTEDO (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual Meeting
04/26/2018 - 18:40 Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL
04/19/2018 - 07:01 Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership
03/26/2018 - 12:01 Teva Announces the Launch of a Generic Version of Lialda in the United States